Messager
Léa Messager, Morlaix FR
Patent application number | Description | Published |
---|---|---|
20150283247 | GLUCOSE RESPONSIVE HYDROGEL COMPRISING PBA-GRAFTED HYALURONIC ACID (HA) - Polymer composition comprising a mixture of PBA modified HA polymer grafted on at least a hydroxyl with a group comprising phenylboronic acid and Cis-diol modified HA polymer grafted on at least a hydroxyl with a group comprising a cis-diol. Injectable or implantable glucose-sensitive hydrogels comprising a this polymer composition. | 10-08-2015 |
Lea Louise Pauline Messager, Morlaix FR
Patent application number | Description | Published |
---|---|---|
20100247445 | POLYMERIC DRUG CARRIER FOR IMAGE-GUIDED DELIVERY - Described are Chemical Exchange-dependent Saturation Transfer (CEST) contrast agents for Magnetic Resonance Imaging (MRI) comprising a polymersome provided with a paramagnetic agent. The polymersome preferably comprises a polymeric shell enclosing a cavity, wherein the cavity comprises a pool of proton analytes, and wherein the shell allows diffusion of the proton analytes. The polymersome-based CEST MRI contrast agents are suitable as drug carriers useful in MRI-guided drug release. | 09-30-2010 |
Sophie Messager, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20100272647 | RECEPTOR - We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4 or a mouse BACH genomic sequence (SEQ ID NO: 10). | 10-28-2010 |
Sophie Messager, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20100158807 | RECEPTOR - We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder. | 06-24-2010 |
Tristan Messager, Pers Jussy FR
Patent application number | Description | Published |
---|---|---|
20110015522 | QUANTIFICATION ANALYSIS OF IMMOBILIZED CONTRAST AGENT IN MEDICAL IMAGING APPLICATIONS - An embodiment of a solution is proposed for analyzing a body part of a patient, which is perfused with a contrast agent capable of circulating within the patient and of being substantially immobilized on a biological target. An embodiment of a corresponding system includes means for providing an echo signal indicative of a response over time to an interrogation signal of the body part, means for associating the echo signal with a model function of time modeling an evolution over time of the contrast agent in the body part, the model function including a combination of a circulation function modeling the circulation of the contrast agent and a decay function modeling a decay of the echo signal from the immobilized contrast agent, and means for estimating at least one kinetics indicator of the contrast agent from the model function. | 01-20-2011 |
Tristan Messager, Geneve CH
Patent application number | Description | Published |
---|---|---|
20090304593 | DETECTION OF THE DETACHMENT OF IMMOBILIZED CONTRAST AGENT IN MEDICAL IMAGING APPLICATIONS - An embodiment of a solution is proposed for imaging a body-part that is perfused with a contrast agent. A corresponding method includes the step of providing a sequence of input images (for example, acquired with an ultrasound scanner); the input images offer a digital representation over time of the body-part. Each input image includes a plurality of input values (i.e., pixel or voxel values); each input value is indicative of a response to an interrogation signal (such as an echo signal for ultrasound waves) of a corresponding location of the body-part, which possibly includes the contrast agent. The method further includes the step of generating at least one filtered image from a plurality of selected ones of the input images (such as all of them or a subset thereof). Each filtered image includes a filtered value for each of a plurality of selected ones of the locations (for example, in a region of interest, or ROI). The filtered value of each selected location is indicative of the contrast agent that leaves the selected location after being substantially stationary at the selected location for a period of time, which is comprised between a first non-zero threshold and a second threshold higher than the first threshold (such as because the contrast agent detaches from the location after having been immobilized thereon, or because it was moving very slowly). The filtered value is obtained by reducing, where present, a contribution of the contrast agent that is substantially stationary at the selected location along the selected input images for a period of time equal to or shorter than the first threshold, and by reducing a contribution of the contrast agent that is substantially stationary at the selected location along the selected input images for a period of time equal to or longer than the second threshold. | 12-10-2009 |